Singapore markets closed

ChemoCentryx, Inc. (CCXI)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
32.50-0.81 (-2.43%)
At close: 04:00PM EST
32.60 +0.10 (+0.31%)
After hours: 07:58PM EST
Full screen
Trade prices are not sourced from all markets
Previous close33.31
Bid32.12 x 900
Ask32.60 x 2200
Day's range30.71 - 33.61
52-week range9.53 - 70.29
Avg. volume1,497,138
Market cap2.276B
Beta (5Y monthly)1.77
PE ratio (TTM)N/A
EPS (TTM)-1.74
Earnings date28 Feb 2022 - 04 Mar 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est72.38
  • Motley Fool

    Why ChemoCentryx Stock Tanked in 2021

    Shares of ChemoCentryx (NASDAQ: CCXI), a mid-cap biopharmaceutical company, fell by a noteworthy 41.2% over the course of 2021, according to data provided by S&P Global Market Intelligence. ANCA-vasculitis is an autoimmune disorder characterized by swelling and damage to small blood vessels. Although the Food and Drug Administration (FDA) ultimately approved Tavneos on Oct. 8, 2021, the drug's fate was far from certain due to a mixed advisory committee (adcom) meeting earlier in the year.

  • Motley Fool

    3 Biotech Stocks That Could Double in 2022

    Here's why they picked Adicet Bio (NASDAQ: ACET), ChemoCentryx (NASDAQ: CCXI), and NRx Pharmaceuticals (NASDAQ: NRXP). ChemoCentryx launched the drug shortly after receiving approval in the U.S. Tavneos is also approved for use in Japan.

  • Zacks

    ChemoCentryx's (CCXI) Stock Increases on Tavneos' FDA Nod

    ChemoCentryx's (CCXI) Tavneos gives a significant boost to the company, following its FDA approval in ANCA-associated vasculitis. The drug is also being evaluated in other indications.